<乌鸦传媒>New Standard for Metastatic HER2 Breast Cancer Consistent PFS, OS benefit with combination including oral HER2 inhibitor tucatinib Dec 11, 2019
<乌鸦传媒>Survival Bump With Oral AML Maintenance Ten-month OS gain, doubling of RFS with oral azacitidine in transplant-ineligible patients Dec 10, 2019
<乌鸦传媒>'Off-the-Shelf' Therapy Active After CAR T-Cell Failure Bispecific antibody mosunetuzumab targets CD3, CD20; needs no ex vivo T-cell processing Dec 07, 2019
<乌鸦传媒>Study Bolsters Case for Novel Xarelto Formulation for Kids Pharmacokinetic data indicate appropriate dosing schemes across wide range of weight categories Dec 07, 2019
<乌鸦传媒>Gene Therapy Hits Its Goal in BCG-Unresponsive NMIBC In phase III trial, 53% achieved complete response at 3 months Dec 06, 2019
<乌鸦传媒>Living Near Oil Refinery Tied to Greater Bladder Cancer Risk Past data support "biological plausibility" for link, says researcher Dec 06, 2019
<乌鸦传媒>Beta Blockers No Help in Advanced Prostate Cancer Findings question earlier retrospective data that pointed to possible survival benefit Dec 05, 2019
<乌鸦传媒>Docetaxel First May Boost Survival in mCRPC Superior outcomes observed versus approach where chemo follows newer agents Dec 05, 2019
<乌鸦传媒>Will Smith Vlogs His First Colonoscopy Actor hopes to bring awareness to important healthcare screening Dec 05, 2019
<乌鸦传媒>More Evidence That Aspirin Can Stave Off Death PLCO follow-up data support protective effect Dec 04, 2019
<乌鸦传媒>MRI-Guided Ultrasound Zaps Low-Risk Prostate Cancer TULSA devices achieves prostate volume reduction Dec 04, 2019
<乌鸦传媒>A Surgical First for Removal of an Appendiceal Neoplasm Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches Nov 25, 2019
<乌鸦传媒>First-Line Combo Improves Survival in Advanced HCC Decreases in overall survival, progression-free survival hazards by almost 50% compared with sorafenib Nov 22, 2019
<乌鸦传媒>Study Suggests Viable Alternative to Mastectomy After In-Breast Recurrence Mastectomy rates low, good cancer control in selected patients Nov 21, 2019
<乌鸦传媒>Surgeon in Spotlight for Excising Soccer Ball-Sized Neck Tumor Called upon for expertise only 4 months into surgical career Nov 19, 2019
<乌鸦传媒>Metastatic Renal Cell Carcinoma: Watch for Brain Mets Present in roughly 5% of patients, survival worse in patients with larger or more lesions Nov 18, 2019
<乌鸦传媒>AHA Dedicates $20 Million to Youth Vaping Research Association and partners aim to "hold e-cigarette companies publicly accountable for their lies" Nov 16, 2019
<乌鸦传媒>Rheumatoid Arthritis Is No Bar to Cancer Immunotherapy Small study finds flares common with checkpoint inhibitors, but few patients stopped treatment because of them Nov 13, 2019
<乌鸦传媒>Abnormal Shadow on Chest Radiograph Culture findings were key in making the diagnosis Nov 11, 2019
<乌鸦传媒>Results Mixed for At-Home HPV Testing Failed to show difference in clinical outcomes despite uptick in screening Nov 06, 2019
<乌鸦传媒>Why the Lower Risk of Prostate Cancer in Men With Diabetes? Findings from large cohort study do not support one leading hypothesis, researchers say Nov 06, 2019
<乌鸦传媒>Low T Therapy After Prostate Ca Surgery Appears Safe But long-term data still lacking Oct 28, 2019
<乌鸦传媒>Sex Assault at Mt. Sinai; Pharma's MD Millionaires; Mammography Marketing Machine This past week in healthcare investigations Oct 23, 2019
<乌鸦传媒>IGHV-Unmutated CLL: Gene Signature May Predict Outcomes After First-Line FCR Prognostic tool may predict who is likely to achieve a relatively long remission Oct 15, 2019
<乌鸦传媒>FCR Still an Option in IGHV-Unmutated CLL? Gene signature identifies lower-risk group with greater chemoimmunotherapy benefit Oct 08, 2019
<乌鸦传媒>First-Line Combo Boosts PFS in Untreated Bladder Cancer 'Clinically meaningful' trend in OS with atezolizumab-chemotherapy Oct 03, 2019
<乌鸦传媒>In Memory of Gerald Chodak, MD Pioneer of active surveillance for men with low-risk prostate cancer died last week Oct 03, 2019
<乌鸦传媒>New Standard in Third-Line Metastatic CRPC Cabazitaxel tops more anti-androgen in patients with "short-ish" response to abiraterone or enzalutamide Oct 01, 2019
<乌鸦传媒>Novel CDK 4/6 Inhibitor Fails in Triple Negative Breast Cancer Misses primary endpoints but has unexpected key benefit Oct 01, 2019
<乌鸦传媒>Neoadjuvant Anti-PD-1 Boosts pCR in TNBC Favorable trend toward improved event-free survival in preliminary analysis Sep 30, 2019
<乌鸦传媒>Trametinib Tx Shows Promise in Tough-to-Treat LGSOC Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer Sep 30, 2019
<乌鸦传媒>Data Support 'Best Drug First' in EGFR-Mutant NSCLC Six-month survival gain with osimertinib, adding to PFS, safety advantages Sep 29, 2019
<乌鸦传媒>CDK 4/6 Inhibitors Boost OS in Advanced Breast Cancer Abemaciclib, ribociclib should become first-line treatment in HR-positive/HER2-negative disease, expert says Sep 29, 2019
<乌鸦传媒>PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Ca? PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines Sep 29, 2019
<乌鸦传媒>Abemaciclib Offers Hope in HR+/HER2+Breast Cancer Phase II monarcHER trial shows better PFS with abemaciclib-trastuzumab-fulvestrant Sep 29, 2019
<乌鸦传媒>First-Line Combo Boosts PFS in Advanced Ovarian Ca Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup Sep 28, 2019
<乌鸦传媒>Advanced HCC Trial Misses OS Endpoint But CheckMate 459 researchers tout "encouraging efficacy and favorable safety profile" Sep 28, 2019
<乌鸦传媒>Notable OS Gains with Dual Immunotherapy in Advanced NSCLC Secondary analysis of CheckMate 227 brings more good news for nivolumab-ipilimumab combo Sep 28, 2019
<乌鸦传媒>BCG Vax: A Shot Against Lung Cancer in Native Populations? 60-year follow-up data from a vaccine trial found surprising results Sep 25, 2019
<乌鸦传媒>Ibrutinib's Cardiotoxicity Comes Into Focus Study identifies new cardiac events linked to so-called targeted therapy Sep 25, 2019
